Examining efficacy and safety of ethyl acetate extract from Allium hirtifolium as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial.

IF 1.9 Q3 CHEMISTRY, MEDICINAL

Avicenna Journal of Phytomedicine Pub Date : 2024-11-01 DOI:10.22038/AJP.2024.24523

Mansour Amin, Mandana Pouladzadeh, Mohammad Jaafar Yadyad, Roshanak Roshanfard, Mohamad Hasan Pipelzadeh, Afshin Talebi, Behzad Sharif Maakhmalzadeh, Mehdi Bijanzadeh, Nasrin Rakipour, Gholamreza Alizadehattar, Seyed Saeed Seyedian, Kambiz Ahmadi Angali, Parastoo Moradi Choghakabodi, Akbar Akbari, Fatemeh Maghsodi, Ebrahim Barzegari, Maryam Jamalan, Reza Aalizadeh, Mostafa Jamalan

{"title":"Examining efficacy and safety of ethyl acetate extract from Allium hirtifolium as complementary therapy in COVID-19: A randomized, multicenter, controlled clinical trial.","authors":"Mansour Amin, Mandana Pouladzadeh, Mohammad Jaafar Yadyad, Roshanak Roshanfard, Mohamad Hasan Pipelzadeh, Afshin Talebi, Behzad Sharif Maakhmalzadeh, Mehdi Bijanzadeh, Nasrin Rakipour, Gholamreza Alizadehattar, Seyed Saeed Seyedian, Kambiz Ahmadi Angali, Parastoo Moradi Choghakabodi, Akbar Akbari, Fatemeh Maghsodi, Ebrahim Barzegari, Maryam Jamalan, Reza Aalizadeh, Mostafa Jamalan","doi":"10.22038/AJP.2024.24523","DOIUrl":null,"url":null,"abstract":"Objective: Given the apparent life-threatening nature of COVID-19, finding an effective treatment is under investigation.Materials and methods: We assessed effect of shallomin oral syrup (co IranAmin®) as a complementary treatment to improve the clinical outcomes in COVID-19 patients. Patients in the control group received the approved treatment protocol (lopinavir/ritonavir), while those in the intervention group were treated with the oral syrup shallomin in addition to the approved treatment. Clinical status of treated patients was recorded and compared.Results: There were meaningful differences between the two groups regarding shortened length of hospital stay and the recovery time for cough, myalgia, sore throat, and shortness of breath. No side effect occurred in the intervention group compared to the control group in terms of biochemical and hematological factors.Conclusion: It seems that the treatment with shallomin syrup showed remarkable contribution to the recovery of COVID-19 induced symptoms in the patients under lopinavir/ritonavir therapy.","PeriodicalId":8677,"journal":{"name":"Avicenna Journal of Phytomedicine","volume":"14 6","pages":"699-710"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12009622/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Avicenna Journal of Phytomedicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22038/AJP.2024.24523","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Given the apparent life-threatening nature of COVID-19, finding an effective treatment is under investigation.

Materials and methods: We assessed effect of shallomin oral syrup (co IranAmin^®) as a complementary treatment to improve the clinical outcomes in COVID-19 patients. Patients in the control group received the approved treatment protocol (lopinavir/ritonavir), while those in the intervention group were treated with the oral syrup shallomin in addition to the approved treatment. Clinical status of treated patients was recorded and compared.

Results: There were meaningful differences between the two groups regarding shortened length of hospital stay and the recovery time for cough, myalgia, sore throat, and shortness of breath. No side effect occurred in the intervention group compared to the control group in terms of biochemical and hematological factors.

Conclusion: It seems that the treatment with shallomin syrup showed remarkable contribution to the recovery of COVID-19 induced symptoms in the patients under lopinavir/ritonavir therapy.

查看原文本刊更多论文

葱乙酸乙酯提取物辅助治疗COVID-19的疗效和安全性：一项随机、多中心、对照临床试验

目的：鉴于COVID-19明显具有威胁生命的性质，正在研究寻找有效的治疗方法。材料与方法：我们评估了shallomin口服糖浆（co IranAmin®）作为补充治疗改善COVID-19患者临床结局的效果。对照组患者接受批准的治疗方案（洛匹那韦/利托那韦），干预组患者在批准治疗的基础上给予口服糖浆沙罗明治疗。记录两组患者的临床情况并进行比较。结果：两组在缩短住院时间和咳嗽、肌痛、喉咙痛、呼吸短促的恢复时间上有显著差异。与对照组相比，干预组在生化和血液学方面均未发生副作用。结论：在接受洛匹那韦/利托那韦治疗的患者中，用沙罗明糖浆治疗对COVID-19诱导症状的恢复有显著的贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊